nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—Dinoprost Tromethamine—HPGDS—testicular cancer	0.0258	0.565	CrCbGaD
Epoprostenol—Dinoprostone—HPGDS—testicular cancer	0.0199	0.435	CrCbGaD
Epoprostenol—PTGIS—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—testicular cancer	0.0127	0.296	CbGpPWpGaD
Epoprostenol—PTGIS—Arachidonic acid metabolism—HPGDS—testicular cancer	0.00459	0.107	CbGpPWpGaD
Epoprostenol—PTGIR—G alpha (s) signalling events—INSL3—testicular cancer	0.00371	0.0863	CbGpPWpGaD
Epoprostenol—PTGIS—female gonad—testicular cancer	0.00359	0.178	CbGeAlD
Epoprostenol—PTGER1—female gonad—testicular cancer	0.00333	0.165	CbGeAlD
Epoprostenol—PTGIS—testis—testicular cancer	0.00318	0.158	CbGeAlD
Epoprostenol—PTGIR—gonad—testicular cancer	0.00253	0.126	CbGeAlD
Epoprostenol—PTGIS—lymph node—testicular cancer	0.00231	0.114	CbGeAlD
Epoprostenol—PTGIR—female gonad—testicular cancer	0.00206	0.102	CbGeAlD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00192	0.0447	CbGpPWpGaD
Epoprostenol—PTGIR—testis—testicular cancer	0.00183	0.0906	CbGeAlD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00177	0.0411	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00177	0.0411	CbGpPWpGaD
Epoprostenol—PTGIS—Biological oxidations—HPGDS—testicular cancer	0.00171	0.0398	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—INSL3—testicular cancer	0.00146	0.034	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—INSL3—testicular cancer	0.00135	0.0313	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—INSL3—testicular cancer	0.00135	0.0313	CbGpPWpGaD
Epoprostenol—PTGIR—lymph node—testicular cancer	0.00132	0.0657	CbGeAlD
Epoprostenol—Hypersensitivity—Ifosfamide—testicular cancer	0.00111	0.00125	CcSEcCtD
Epoprostenol—Abdominal distension—Doxorubicin—testicular cancer	0.00109	0.00123	CcSEcCtD
Epoprostenol—Asthenia—Ifosfamide—testicular cancer	0.00108	0.00121	CcSEcCtD
Epoprostenol—Sweating—Methotrexate—testicular cancer	0.00107	0.0012	CcSEcCtD
Epoprostenol—Paraesthesia—Etoposide—testicular cancer	0.00107	0.0012	CcSEcCtD
Epoprostenol—Pruritus—Ifosfamide—testicular cancer	0.00107	0.0012	CcSEcCtD
Epoprostenol—Haematuria—Methotrexate—testicular cancer	0.00107	0.0012	CcSEcCtD
Epoprostenol—Weight decreased—Epirubicin—testicular cancer	0.00106	0.00119	CcSEcCtD
Epoprostenol—Dyspnoea—Etoposide—testicular cancer	0.00106	0.00119	CcSEcCtD
Epoprostenol—Somnolence—Etoposide—testicular cancer	0.00106	0.00119	CcSEcCtD
Epoprostenol—Epistaxis—Methotrexate—testicular cancer	0.00105	0.00118	CcSEcCtD
Epoprostenol—Pneumonia—Epirubicin—testicular cancer	0.00105	0.00118	CcSEcCtD
Epoprostenol—Nausea—Bleomycin—testicular cancer	0.00105	0.00118	CcSEcCtD
Epoprostenol—Infestation NOS—Epirubicin—testicular cancer	0.00105	0.00117	CcSEcCtD
Epoprostenol—Infestation—Epirubicin—testicular cancer	0.00105	0.00117	CcSEcCtD
Epoprostenol—Vomiting—Dactinomycin—testicular cancer	0.00105	0.00117	CcSEcCtD
Epoprostenol—Rash—Dactinomycin—testicular cancer	0.00104	0.00116	CcSEcCtD
Epoprostenol—Decreased appetite—Etoposide—testicular cancer	0.00103	0.00116	CcSEcCtD
Epoprostenol—Diarrhoea—Ifosfamide—testicular cancer	0.00103	0.00116	CcSEcCtD
Epoprostenol—Pancytopenia—Doxorubicin—testicular cancer	0.00103	0.00116	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Etoposide—testicular cancer	0.00103	0.00115	CcSEcCtD
Epoprostenol—Body temperature increased—Cisplatin—testicular cancer	0.00103	0.00115	CcSEcCtD
Epoprostenol—Fatigue—Etoposide—testicular cancer	0.00103	0.00115	CcSEcCtD
Epoprostenol—Constipation—Etoposide—testicular cancer	0.00102	0.00114	CcSEcCtD
Epoprostenol—Pain—Etoposide—testicular cancer	0.00102	0.00114	CcSEcCtD
Epoprostenol—Urinary tract infection—Epirubicin—testicular cancer	0.00102	0.00114	CcSEcCtD
Epoprostenol—Haemoglobin—Methotrexate—testicular cancer	0.00101	0.00113	CcSEcCtD
Epoprostenol—Haemorrhage—Methotrexate—testicular cancer	0.001	0.00113	CcSEcCtD
Epoprostenol—Sweating—Epirubicin—testicular cancer	0.001	0.00113	CcSEcCtD
Epoprostenol—Haematuria—Epirubicin—testicular cancer	0.000997	0.00112	CcSEcCtD
Epoprostenol—Dizziness—Ifosfamide—testicular cancer	0.000997	0.00112	CcSEcCtD
Epoprostenol—Pharyngitis—Methotrexate—testicular cancer	0.000996	0.00112	CcSEcCtD
Epoprostenol—Epistaxis—Epirubicin—testicular cancer	0.000987	0.00111	CcSEcCtD
Epoprostenol—Weight decreased—Doxorubicin—testicular cancer	0.000982	0.0011	CcSEcCtD
Epoprostenol—Sinusitis—Epirubicin—testicular cancer	0.000981	0.0011	CcSEcCtD
Epoprostenol—Nausea—Dactinomycin—testicular cancer	0.000977	0.0011	CcSEcCtD
Epoprostenol—Pneumonia—Doxorubicin—testicular cancer	0.000974	0.00109	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Etoposide—testicular cancer	0.000973	0.00109	CcSEcCtD
Epoprostenol—Infestation NOS—Doxorubicin—testicular cancer	0.000968	0.00109	CcSEcCtD
Epoprostenol—Infestation—Doxorubicin—testicular cancer	0.000968	0.00109	CcSEcCtD
Epoprostenol—Vomiting—Ifosfamide—testicular cancer	0.000958	0.00108	CcSEcCtD
Epoprostenol—Hypersensitivity—Cisplatin—testicular cancer	0.000957	0.00107	CcSEcCtD
Epoprostenol—Bradycardia—Epirubicin—testicular cancer	0.000956	0.00107	CcSEcCtD
Epoprostenol—Rash—Ifosfamide—testicular cancer	0.00095	0.00107	CcSEcCtD
Epoprostenol—Dermatitis—Ifosfamide—testicular cancer	0.000949	0.00107	CcSEcCtD
Epoprostenol—Urticaria—Etoposide—testicular cancer	0.000946	0.00106	CcSEcCtD
Epoprostenol—Haemoglobin—Epirubicin—testicular cancer	0.000944	0.00106	CcSEcCtD
Epoprostenol—Rhinitis—Epirubicin—testicular cancer	0.000941	0.00106	CcSEcCtD
Epoprostenol—Body temperature increased—Etoposide—testicular cancer	0.000941	0.00106	CcSEcCtD
Epoprostenol—Abdominal pain—Etoposide—testicular cancer	0.000941	0.00106	CcSEcCtD
Epoprostenol—Urinary tract infection—Doxorubicin—testicular cancer	0.000941	0.00106	CcSEcCtD
Epoprostenol—Haemorrhage—Epirubicin—testicular cancer	0.000939	0.00105	CcSEcCtD
Epoprostenol—Hypoaesthesia—Epirubicin—testicular cancer	0.000934	0.00105	CcSEcCtD
Epoprostenol—Asthenia—Cisplatin—testicular cancer	0.000932	0.00105	CcSEcCtD
Epoprostenol—Pharyngitis—Epirubicin—testicular cancer	0.000932	0.00105	CcSEcCtD
Epoprostenol—Cardiac disorder—Methotrexate—testicular cancer	0.000931	0.00104	CcSEcCtD
Epoprostenol—Sweating—Doxorubicin—testicular cancer	0.000928	0.00104	CcSEcCtD
Epoprostenol—Oedema peripheral—Epirubicin—testicular cancer	0.000925	0.00104	CcSEcCtD
Epoprostenol—Haematuria—Doxorubicin—testicular cancer	0.000923	0.00104	CcSEcCtD
Epoprostenol—Connective tissue disorder—Epirubicin—testicular cancer	0.000923	0.00104	CcSEcCtD
Epoprostenol—Epistaxis—Doxorubicin—testicular cancer	0.000913	0.00102	CcSEcCtD
Epoprostenol—Angiopathy—Methotrexate—testicular cancer	0.00091	0.00102	CcSEcCtD
Epoprostenol—Sinusitis—Doxorubicin—testicular cancer	0.000908	0.00102	CcSEcCtD
Epoprostenol—Mediastinal disorder—Methotrexate—testicular cancer	0.000904	0.00101	CcSEcCtD
Epoprostenol—Chills—Methotrexate—testicular cancer	0.0009	0.00101	CcSEcCtD
Epoprostenol—Nausea—Ifosfamide—testicular cancer	0.000895	0.001	CcSEcCtD
Epoprostenol—Diarrhoea—Cisplatin—testicular cancer	0.000889	0.000997	CcSEcCtD
Epoprostenol—Bradycardia—Doxorubicin—testicular cancer	0.000885	0.000993	CcSEcCtD
Epoprostenol—Mental disorder—Methotrexate—testicular cancer	0.000879	0.000986	CcSEcCtD
Epoprostenol—Hypersensitivity—Etoposide—testicular cancer	0.000877	0.000984	CcSEcCtD
Epoprostenol—Haemoglobin—Doxorubicin—testicular cancer	0.000873	0.00098	CcSEcCtD
Epoprostenol—Cardiac disorder—Epirubicin—testicular cancer	0.000872	0.000978	CcSEcCtD
Epoprostenol—Flushing—Epirubicin—testicular cancer	0.000872	0.000978	CcSEcCtD
Epoprostenol—Rhinitis—Doxorubicin—testicular cancer	0.000871	0.000977	CcSEcCtD
Epoprostenol—Haemorrhage—Doxorubicin—testicular cancer	0.000869	0.000975	CcSEcCtD
Epoprostenol—Hypoaesthesia—Doxorubicin—testicular cancer	0.000865	0.00097	CcSEcCtD
Epoprostenol—Pharyngitis—Doxorubicin—testicular cancer	0.000862	0.000968	CcSEcCtD
Epoprostenol—Oedema peripheral—Doxorubicin—testicular cancer	0.000856	0.00096	CcSEcCtD
Epoprostenol—Asthenia—Etoposide—testicular cancer	0.000854	0.000958	CcSEcCtD
Epoprostenol—Connective tissue disorder—Doxorubicin—testicular cancer	0.000854	0.000958	CcSEcCtD
Epoprostenol—Angiopathy—Epirubicin—testicular cancer	0.000852	0.000956	CcSEcCtD
Epoprostenol—Mediastinal disorder—Epirubicin—testicular cancer	0.000846	0.00095	CcSEcCtD
Epoprostenol—Back pain—Methotrexate—testicular cancer	0.000845	0.000948	CcSEcCtD
Epoprostenol—Chills—Epirubicin—testicular cancer	0.000843	0.000945	CcSEcCtD
Epoprostenol—Pruritus—Etoposide—testicular cancer	0.000842	0.000945	CcSEcCtD
Epoprostenol—P2RY12—GPCR downstream signaling—INSL3—testicular cancer	0.000827	0.0192	CbGpPWpGaD
Epoprostenol—Vomiting—Cisplatin—testicular cancer	0.000826	0.000927	CcSEcCtD
Epoprostenol—Mental disorder—Epirubicin—testicular cancer	0.000823	0.000923	CcSEcCtD
Epoprostenol—Rash—Cisplatin—testicular cancer	0.000819	0.000919	CcSEcCtD
Epoprostenol—Dermatitis—Cisplatin—testicular cancer	0.000818	0.000918	CcSEcCtD
Epoprostenol—Diarrhoea—Etoposide—testicular cancer	0.000814	0.000914	CcSEcCtD
Epoprostenol—Anaemia—Methotrexate—testicular cancer	0.000807	0.000906	CcSEcCtD
Epoprostenol—Cardiac disorder—Doxorubicin—testicular cancer	0.000806	0.000905	CcSEcCtD
Epoprostenol—Flushing—Doxorubicin—testicular cancer	0.000806	0.000905	CcSEcCtD
Epoprostenol—Flatulence—Epirubicin—testicular cancer	0.000806	0.000904	CcSEcCtD
Epoprostenol—Tension—Epirubicin—testicular cancer	0.000802	0.0009	CcSEcCtD
Epoprostenol—Nervousness—Epirubicin—testicular cancer	0.000794	0.000891	CcSEcCtD
Epoprostenol—Back pain—Epirubicin—testicular cancer	0.000791	0.000887	CcSEcCtD
Epoprostenol—Angiopathy—Doxorubicin—testicular cancer	0.000788	0.000885	CcSEcCtD
Epoprostenol—Dizziness—Etoposide—testicular cancer	0.000787	0.000883	CcSEcCtD
Epoprostenol—Muscle spasms—Epirubicin—testicular cancer	0.000786	0.000882	CcSEcCtD
Epoprostenol—Mediastinal disorder—Doxorubicin—testicular cancer	0.000783	0.000879	CcSEcCtD
Epoprostenol—Chills—Doxorubicin—testicular cancer	0.00078	0.000875	CcSEcCtD
Epoprostenol—Nausea—Cisplatin—testicular cancer	0.000772	0.000866	CcSEcCtD
Epoprostenol—Cough—Methotrexate—testicular cancer	0.000762	0.000855	CcSEcCtD
Epoprostenol—Mental disorder—Doxorubicin—testicular cancer	0.000761	0.000854	CcSEcCtD
Epoprostenol—PTGER1—GPCR downstream signaling—INSL3—testicular cancer	0.000761	0.0177	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—INSL3—testicular cancer	0.000761	0.0177	CbGpPWpGaD
Epoprostenol—Vomiting—Etoposide—testicular cancer	0.000757	0.000849	CcSEcCtD
Epoprostenol—Anaemia—Epirubicin—testicular cancer	0.000756	0.000848	CcSEcCtD
Epoprostenol—Agitation—Epirubicin—testicular cancer	0.000751	0.000843	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—INSL3—testicular cancer	0.000751	0.0175	CbGpPWpGaD
Epoprostenol—Rash—Etoposide—testicular cancer	0.00075	0.000842	CcSEcCtD
Epoprostenol—Dermatitis—Etoposide—testicular cancer	0.00075	0.000841	CcSEcCtD
Epoprostenol—Headache—Etoposide—testicular cancer	0.000746	0.000837	CcSEcCtD
Epoprostenol—Flatulence—Doxorubicin—testicular cancer	0.000745	0.000836	CcSEcCtD
Epoprostenol—Myalgia—Methotrexate—testicular cancer	0.000744	0.000834	CcSEcCtD
Epoprostenol—Chest pain—Methotrexate—testicular cancer	0.000744	0.000834	CcSEcCtD
Epoprostenol—Arthralgia—Methotrexate—testicular cancer	0.000744	0.000834	CcSEcCtD
Epoprostenol—Tension—Doxorubicin—testicular cancer	0.000742	0.000833	CcSEcCtD
Epoprostenol—CYP2C9—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000741	0.0173	CbGpPWpGaD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000739	0.000829	CcSEcCtD
Epoprostenol—Nervousness—Doxorubicin—testicular cancer	0.000735	0.000824	CcSEcCtD
Epoprostenol—Syncope—Epirubicin—testicular cancer	0.000733	0.000823	CcSEcCtD
Epoprostenol—Back pain—Doxorubicin—testicular cancer	0.000732	0.000821	CcSEcCtD
Epoprostenol—Muscle spasms—Doxorubicin—testicular cancer	0.000727	0.000816	CcSEcCtD
Epoprostenol—Palpitations—Epirubicin—testicular cancer	0.000722	0.000811	CcSEcCtD
Epoprostenol—Confusional state—Methotrexate—testicular cancer	0.000719	0.000807	CcSEcCtD
Epoprostenol—Loss of consciousness—Epirubicin—testicular cancer	0.000719	0.000806	CcSEcCtD
Epoprostenol—Cough—Epirubicin—testicular cancer	0.000713	0.0008	CcSEcCtD
Epoprostenol—Anaphylactic shock—Methotrexate—testicular cancer	0.000713	0.0008	CcSEcCtD
Epoprostenol—Infection—Methotrexate—testicular cancer	0.000708	0.000795	CcSEcCtD
Epoprostenol—Nausea—Etoposide—testicular cancer	0.000707	0.000793	CcSEcCtD
Epoprostenol—Nervous system disorder—Methotrexate—testicular cancer	0.000699	0.000784	CcSEcCtD
Epoprostenol—Anaemia—Doxorubicin—testicular cancer	0.000699	0.000784	CcSEcCtD
Epoprostenol—Thrombocytopenia—Methotrexate—testicular cancer	0.000698	0.000783	CcSEcCtD
Epoprostenol—Chest pain—Epirubicin—testicular cancer	0.000696	0.000781	CcSEcCtD
Epoprostenol—Myalgia—Epirubicin—testicular cancer	0.000696	0.000781	CcSEcCtD
Epoprostenol—Arthralgia—Epirubicin—testicular cancer	0.000696	0.000781	CcSEcCtD
Epoprostenol—Agitation—Doxorubicin—testicular cancer	0.000695	0.00078	CcSEcCtD
Epoprostenol—Anxiety—Epirubicin—testicular cancer	0.000694	0.000778	CcSEcCtD
Epoprostenol—Skin disorder—Methotrexate—testicular cancer	0.000692	0.000777	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000691	0.000776	CcSEcCtD
Epoprostenol—PTGIR—Signaling by GPCR—INSL3—testicular cancer	0.000691	0.0161	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—INSL3—testicular cancer	0.000691	0.0161	CbGpPWpGaD
Epoprostenol—Hyperhidrosis—Methotrexate—testicular cancer	0.000689	0.000773	CcSEcCtD
Epoprostenol—Dry mouth—Epirubicin—testicular cancer	0.000681	0.000764	CcSEcCtD
Epoprostenol—Anorexia—Methotrexate—testicular cancer	0.00068	0.000763	CcSEcCtD
Epoprostenol—Syncope—Doxorubicin—testicular cancer	0.000678	0.000761	CcSEcCtD
Epoprostenol—Confusional state—Epirubicin—testicular cancer	0.000673	0.000755	CcSEcCtD
Epoprostenol—Palpitations—Doxorubicin—testicular cancer	0.000668	0.00075	CcSEcCtD
Epoprostenol—Oedema—Epirubicin—testicular cancer	0.000667	0.000749	CcSEcCtD
Epoprostenol—Anaphylactic shock—Epirubicin—testicular cancer	0.000667	0.000749	CcSEcCtD
Epoprostenol—Hypotension—Methotrexate—testicular cancer	0.000666	0.000747	CcSEcCtD
Epoprostenol—Loss of consciousness—Doxorubicin—testicular cancer	0.000665	0.000746	CcSEcCtD
Epoprostenol—Infection—Epirubicin—testicular cancer	0.000663	0.000744	CcSEcCtD
Epoprostenol—Cough—Doxorubicin—testicular cancer	0.00066	0.000741	CcSEcCtD
Epoprostenol—Shock—Epirubicin—testicular cancer	0.000656	0.000737	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000656	0.0153	CbGpPWpGaD
Epoprostenol—Nervous system disorder—Epirubicin—testicular cancer	0.000654	0.000734	CcSEcCtD
Epoprostenol—Thrombocytopenia—Epirubicin—testicular cancer	0.000653	0.000733	CcSEcCtD
Epoprostenol—Tachycardia—Epirubicin—testicular cancer	0.000651	0.000731	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.00065	0.000729	CcSEcCtD
Epoprostenol—Skin disorder—Epirubicin—testicular cancer	0.000648	0.000727	CcSEcCtD
Epoprostenol—Hyperhidrosis—Epirubicin—testicular cancer	0.000645	0.000724	CcSEcCtD
Epoprostenol—Insomnia—Methotrexate—testicular cancer	0.000645	0.000724	CcSEcCtD
Epoprostenol—Arthralgia—Doxorubicin—testicular cancer	0.000644	0.000723	CcSEcCtD
Epoprostenol—Myalgia—Doxorubicin—testicular cancer	0.000644	0.000723	CcSEcCtD
Epoprostenol—Chest pain—Doxorubicin—testicular cancer	0.000644	0.000723	CcSEcCtD
Epoprostenol—Anxiety—Doxorubicin—testicular cancer	0.000642	0.00072	CcSEcCtD
Epoprostenol—Paraesthesia—Methotrexate—testicular cancer	0.00064	0.000718	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.00064	0.000718	CcSEcCtD
Epoprostenol—Anorexia—Epirubicin—testicular cancer	0.000636	0.000714	CcSEcCtD
Epoprostenol—Dyspnoea—Methotrexate—testicular cancer	0.000636	0.000713	CcSEcCtD
Epoprostenol—Somnolence—Methotrexate—testicular cancer	0.000634	0.000711	CcSEcCtD
Epoprostenol—Dry mouth—Doxorubicin—testicular cancer	0.00063	0.000707	CcSEcCtD
Epoprostenol—Dyspepsia—Methotrexate—testicular cancer	0.000628	0.000704	CcSEcCtD
Epoprostenol—Hypotension—Epirubicin—testicular cancer	0.000623	0.0007	CcSEcCtD
Epoprostenol—Confusional state—Doxorubicin—testicular cancer	0.000622	0.000698	CcSEcCtD
Epoprostenol—Decreased appetite—Methotrexate—testicular cancer	0.00062	0.000695	CcSEcCtD
Epoprostenol—Oedema—Doxorubicin—testicular cancer	0.000617	0.000693	CcSEcCtD
Epoprostenol—Anaphylactic shock—Doxorubicin—testicular cancer	0.000617	0.000693	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000615	0.000691	CcSEcCtD
Epoprostenol—Fatigue—Methotrexate—testicular cancer	0.000615	0.00069	CcSEcCtD
Epoprostenol—Infection—Doxorubicin—testicular cancer	0.000613	0.000688	CcSEcCtD
Epoprostenol—Pain—Methotrexate—testicular cancer	0.00061	0.000684	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000608	0.000682	CcSEcCtD
Epoprostenol—Shock—Doxorubicin—testicular cancer	0.000607	0.000681	CcSEcCtD
Epoprostenol—Nervous system disorder—Doxorubicin—testicular cancer	0.000605	0.000679	CcSEcCtD
Epoprostenol—Thrombocytopenia—Doxorubicin—testicular cancer	0.000604	0.000678	CcSEcCtD
Epoprostenol—Insomnia—Epirubicin—testicular cancer	0.000603	0.000677	CcSEcCtD
Epoprostenol—Tachycardia—Doxorubicin—testicular cancer	0.000602	0.000676	CcSEcCtD
Epoprostenol—Skin disorder—Doxorubicin—testicular cancer	0.0006	0.000673	CcSEcCtD
Epoprostenol—Paraesthesia—Epirubicin—testicular cancer	0.000599	0.000672	CcSEcCtD
Epoprostenol—Hyperhidrosis—Doxorubicin—testicular cancer	0.000597	0.00067	CcSEcCtD
Epoprostenol—Dyspnoea—Epirubicin—testicular cancer	0.000595	0.000667	CcSEcCtD
Epoprostenol—Somnolence—Epirubicin—testicular cancer	0.000593	0.000666	CcSEcCtD
Epoprostenol—Anorexia—Doxorubicin—testicular cancer	0.000588	0.00066	CcSEcCtD
Epoprostenol—Dyspepsia—Epirubicin—testicular cancer	0.000587	0.000659	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Methotrexate—testicular cancer	0.000583	0.000654	CcSEcCtD
Epoprostenol—Decreased appetite—Epirubicin—testicular cancer	0.00058	0.000651	CcSEcCtD
Epoprostenol—Hypotension—Doxorubicin—testicular cancer	0.000577	0.000647	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000576	0.000646	CcSEcCtD
Epoprostenol—Fatigue—Epirubicin—testicular cancer	0.000575	0.000645	CcSEcCtD
Epoprostenol—Pain—Epirubicin—testicular cancer	0.000571	0.00064	CcSEcCtD
Epoprostenol—Constipation—Epirubicin—testicular cancer	0.000571	0.00064	CcSEcCtD
Epoprostenol—Urticaria—Methotrexate—testicular cancer	0.000566	0.000635	CcSEcCtD
Epoprostenol—Abdominal pain—Methotrexate—testicular cancer	0.000564	0.000632	CcSEcCtD
Epoprostenol—Body temperature increased—Methotrexate—testicular cancer	0.000564	0.000632	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000562	0.000631	CcSEcCtD
Epoprostenol—Insomnia—Doxorubicin—testicular cancer	0.000558	0.000627	CcSEcCtD
Epoprostenol—Paraesthesia—Doxorubicin—testicular cancer	0.000554	0.000622	CcSEcCtD
Epoprostenol—Dyspnoea—Doxorubicin—testicular cancer	0.00055	0.000618	CcSEcCtD
Epoprostenol—Somnolence—Doxorubicin—testicular cancer	0.000549	0.000616	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Epirubicin—testicular cancer	0.000546	0.000612	CcSEcCtD
Epoprostenol—Dyspepsia—Doxorubicin—testicular cancer	0.000543	0.00061	CcSEcCtD
Epoprostenol—Decreased appetite—Doxorubicin—testicular cancer	0.000537	0.000602	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000533	0.000598	CcSEcCtD
Epoprostenol—Fatigue—Doxorubicin—testicular cancer	0.000532	0.000597	CcSEcCtD
Epoprostenol—Urticaria—Epirubicin—testicular cancer	0.00053	0.000595	CcSEcCtD
Epoprostenol—Constipation—Doxorubicin—testicular cancer	0.000528	0.000592	CcSEcCtD
Epoprostenol—Pain—Doxorubicin—testicular cancer	0.000528	0.000592	CcSEcCtD
Epoprostenol—Abdominal pain—Epirubicin—testicular cancer	0.000527	0.000592	CcSEcCtD
Epoprostenol—Body temperature increased—Epirubicin—testicular cancer	0.000527	0.000592	CcSEcCtD
Epoprostenol—Hypersensitivity—Methotrexate—testicular cancer	0.000525	0.000589	CcSEcCtD
Epoprostenol—Asthenia—Methotrexate—testicular cancer	0.000512	0.000574	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000505	0.000566	CcSEcCtD
Epoprostenol—Pruritus—Methotrexate—testicular cancer	0.000504	0.000566	CcSEcCtD
Epoprostenol—Hypersensitivity—Epirubicin—testicular cancer	0.000492	0.000552	CcSEcCtD
Epoprostenol—Urticaria—Doxorubicin—testicular cancer	0.00049	0.00055	CcSEcCtD
Epoprostenol—Abdominal pain—Doxorubicin—testicular cancer	0.000488	0.000548	CcSEcCtD
Epoprostenol—Body temperature increased—Doxorubicin—testicular cancer	0.000488	0.000548	CcSEcCtD
Epoprostenol—Diarrhoea—Methotrexate—testicular cancer	0.000488	0.000547	CcSEcCtD
Epoprostenol—Asthenia—Epirubicin—testicular cancer	0.000479	0.000537	CcSEcCtD
Epoprostenol—Pruritus—Epirubicin—testicular cancer	0.000472	0.00053	CcSEcCtD
Epoprostenol—Dizziness—Methotrexate—testicular cancer	0.000471	0.000529	CcSEcCtD
Epoprostenol—Diarrhoea—Epirubicin—testicular cancer	0.000456	0.000512	CcSEcCtD
Epoprostenol—Hypersensitivity—Doxorubicin—testicular cancer	0.000455	0.00051	CcSEcCtD
Epoprostenol—Vomiting—Methotrexate—testicular cancer	0.000453	0.000509	CcSEcCtD
Epoprostenol—Rash—Methotrexate—testicular cancer	0.00045	0.000504	CcSEcCtD
Epoprostenol—Dermatitis—Methotrexate—testicular cancer	0.000449	0.000504	CcSEcCtD
Epoprostenol—Headache—Methotrexate—testicular cancer	0.000447	0.000501	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—INSL3—testicular cancer	0.000443	0.0103	CbGpPWpGaD
Epoprostenol—Asthenia—Doxorubicin—testicular cancer	0.000443	0.000497	CcSEcCtD
Epoprostenol—Dizziness—Epirubicin—testicular cancer	0.000441	0.000495	CcSEcCtD
Epoprostenol—Pruritus—Doxorubicin—testicular cancer	0.000437	0.00049	CcSEcCtD
Epoprostenol—Vomiting—Epirubicin—testicular cancer	0.000424	0.000476	CcSEcCtD
Epoprostenol—Nausea—Methotrexate—testicular cancer	0.000423	0.000475	CcSEcCtD
Epoprostenol—Diarrhoea—Doxorubicin—testicular cancer	0.000422	0.000474	CcSEcCtD
Epoprostenol—Rash—Epirubicin—testicular cancer	0.000421	0.000472	CcSEcCtD
Epoprostenol—Dermatitis—Epirubicin—testicular cancer	0.00042	0.000472	CcSEcCtD
Epoprostenol—Headache—Epirubicin—testicular cancer	0.000418	0.000469	CcSEcCtD
Epoprostenol—Dizziness—Doxorubicin—testicular cancer	0.000408	0.000458	CcSEcCtD
Epoprostenol—PTGIR—Signaling Pathways—INSL3—testicular cancer	0.000408	0.0095	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—INSL3—testicular cancer	0.000408	0.0095	CbGpPWpGaD
Epoprostenol—Nausea—Epirubicin—testicular cancer	0.000396	0.000445	CcSEcCtD
Epoprostenol—Vomiting—Doxorubicin—testicular cancer	0.000393	0.00044	CcSEcCtD
Epoprostenol—Rash—Doxorubicin—testicular cancer	0.000389	0.000437	CcSEcCtD
Epoprostenol—Dermatitis—Doxorubicin—testicular cancer	0.000389	0.000436	CcSEcCtD
Epoprostenol—Headache—Doxorubicin—testicular cancer	0.000387	0.000434	CcSEcCtD
Epoprostenol—Nausea—Doxorubicin—testicular cancer	0.000367	0.000411	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—HPGDS—testicular cancer	0.000292	0.0068	CbGpPWpGaD
Epoprostenol—CYP2C9—Biological oxidations—HPGDS—testicular cancer	0.000276	0.00642	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—H2AFZ—testicular cancer	0.000255	0.00593	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—KITLG—testicular cancer	0.000234	0.00546	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—STK11—testicular cancer	0.000212	0.00494	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—FGFR3—testicular cancer	0.000174	0.00406	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—KIT—testicular cancer	0.00016	0.00372	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—H2AFZ—testicular cancer	0.000142	0.0033	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—STK11—testicular cancer	0.000141	0.00329	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—H2AFZ—testicular cancer	0.000131	0.00304	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—H2AFZ—testicular cancer	0.000131	0.00304	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KITLG—testicular cancer	0.000131	0.00304	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—STK11—testicular cancer	0.00013	0.00302	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—STK11—testicular cancer	0.00013	0.00302	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KITLG—testicular cancer	0.00012	0.0028	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KITLG—testicular cancer	0.00012	0.0028	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000106	0.00247	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—FGFR3—testicular cancer	9.7e-05	0.00226	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—FGFR3—testicular cancer	8.93e-05	0.00208	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—FGFR3—testicular cancer	8.93e-05	0.00208	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KIT—testicular cancer	8.91e-05	0.00207	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KIT—testicular cancer	8.2e-05	0.00191	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KIT—testicular cancer	8.2e-05	0.00191	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HPGDS—testicular cancer	4.72e-05	0.0011	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—STK11—testicular cancer	3.43e-05	0.000798	CbGpPWpGaD
